FDA's Novantrone concerns

WASHINGTON -- The FDA today began implementation of its court-mandated disclosure of advisory panel documents, disclosing the issues it is weighing in its review of Immunex Corp.'s application for approval of Novantrone mitoxantrone to slow progression of neurologic disability and reduce the relapse rate in patients with progressive multiple sclerosis.

The hundreds of pages of review materials posted on the

Read the full 604 word article

How to gain access

Continue reading with a
two-week free trial.